Further to your thoughts BKC; the other thing RVX and Zenith have in common is an apparent leadership position in clinical research relating to epigenetics. Both companies also apparently have numerous compounds of interest in this field as well as interesting lead clinical candidates. Epigenetics is becoming more and more front and center as a bright spot in the future of medicine. From a business perspective, if a pharma was considering buying an epigentics patform it would seem that RVX and Zenith might provide an attractive risk adjusted opportunity but if you were going to buy one you would likely want both due to potential competitive/IP considerations. Speculation for sure but who knows?